| mRNA |
linifanib |
GDSC1000 |
pan-cancer |
AAC |
0.26 |
6e-12 |
| mRNA |
ABT-737 |
CTRPv2 |
pan-cancer |
AAC |
0.24 |
5e-10 |
| mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.24 |
1e-09 |
| mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
7e-08 |
| mRNA |
selumetinib:tretinoin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
1e-07 |
| mRNA |
cabozantinib |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
4e-07 |
| mRNA |
AZD6244 |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
6e-07 |
| mRNA |
selumetinib:BRD-A02303741 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
8e-07 |
| mRNA |
NVP-BSK805 |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
1e-06 |
| mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
1e-06 |